Join the Chronic Kidney Disease group to help and get support from people like you.
Chronic Kidney Disease News (Page 5)
Related terms: CKD, Chronic Renal Disease, CRD
ACEi, ARB Use Linked to Lower Risk for Kidney Failure With Replacement Therapy
MONDAY, July 8, 2024 – For individuals with advanced chronic kidney disease (CKD), angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) treatment is associated with a...
Few With Type 2 Diabetes Receive Guideline-Recommended CKD Screening
MONDAY, July 1, 2024 – Fewer than one-quarter of patients with type 2 diabetes (T2D) receive recommended chronic kidney disease (CKD) screening, according to a study published online June 26 in JAMA...
US FDA Approves Jardiance for the Treatment of Adults with Chronic Kidney Disease
RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 22, 2023 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained ...
FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
WHIPPANY, N.J.-- July 9, 2021 (BUSINESS WIRE)-- Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal...
Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes
30 April 2021 Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction...
FDA Approves Auryxia (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
BOSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) – Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to people with kidney disease, today announced that the U.S....
FDA Approves Amgen's Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis
THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv (etelcalcetide) for the treatment of...
FDA Approves Rayaldee (calcifediol) to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease
MIAMI--(BUSINESS WIRE) June 21, 2016 – OPKO Health, Inc. (NYSE:OPK) announced that the U.S. Food and Drug Administration (FDA) has approved Rayaldee (calcifediol) extended release capsules for the...